3rd Quarter - Report

VAN HEUVELEN STRATEGIES, LLC for ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)

Period 3rd Quarter 2014 Filed Oct 20, 2014 Signed by Robert Van Heuvelen

Official filing
Firm
VAN HEUVELEN STRATEGIES, LLC
Client
ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Labor Issues/Antitrust/Workplace LBR

Prescription drug user fee act and other issues related to generic drugs H.R. 3204 - Drug Quality and Security Act H.R. 3309 - Innovation Act S. 1013 - Patent Abuse Reduction Act of 2013 S. 1612 - Patent litigation and Integrity Act of 2013 S. 1720 - Patent Transparency and Improvements Act of 2013 S. 2049 - Transparency in Assertion of Patents Act

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3204 (113th), H.R. 3309 (113th), S. 1720 (113th), S. 1612 (113th), S. 1013 (113th), S. 2049 (113th)

Taxation/Internal Revenue Code TAX

S. 2768 - Corporate Inverters Earnings Stripping Reform Act of 2014 S. 2540 - Patriot Employer Tax Credit Act

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2768 (113th), S. 2540 (113th)

Health Issues HCR

Prescription drug user fee act and other issues related to generic drugs H.R. 3204 - Drug Quality and Security Act H.R. 3309 - Innovation Act S. 1013 - Patent Abuse Reduction Act of 2013 S. 1612 - Patent litigation and Integrity Act of 2013 S. 1720 - Patent Transparency and Improvements Act of 2013 S. 2049 - Transparency in Assertion of Patents Act

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1013 (113th), H.R. 3309 (113th), S. 2049 (113th), S. 1720 (113th), S. 1612 (113th), H.R. 3204 (113th)

Budget/Appropriations BUD

Prescription drug user fee act and other issues related to generic drugs H.R. 3204 - Drug Quality and Security Act H.R. 3309 - Innovation Act S. 1013 - Patent Abuse Reduction Act of 2013 S. 1612 - Patent litigation and Integrity Act of 2013 S. 1720 - Patent Transparency and Improvements Act of 2013 S. 2049 - Transparency in Assertion of Patents Act

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1612 (113th), S. 1720 (113th), S. 2049 (113th), H.R. 3309 (113th), H.R. 3204 (113th), S. 1013 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.